Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: Imidazo[4,5-c]quinoline compounds of Formula (I) having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: A method includes applying an electrical signal to a tissue and measuring an impedance of the tissue based on the applied electrical signal. The method further includes determining information indicative of a stage of wound healing based on the impedance and outputting information indicative of the stage of wound healing.

Abstract: A method and system for tissue impedance measurement are disclosed. In examples, the system comprises electrical contacts configured to be coupled to a first tissue and a first device configured to apply a first electrical signal to the first tissue via the electrical contacts. The system further comprises a second device configured to determine a first impedance phase angle of epithelial tissue of the first tissue site based on the first applied electrical signal, determine a baseline impedance phase angle of epithelial tissue corresponding to a second tissue, determine information indicative of epithelial tissue characteristics based on a ratio of the first impedance phase angle and the baseline impedance phase angle, and output information indicative of the epithelial tissue characteristics.

Abstract: A method of applying a two-part dental sealant is described comprising providing a syringe device (1) comprising a cartridge (10) including first and second chamber. The first chamber contains a first part of a dental sealant comprising a (meth)acrylate resin and an oxidizing curing agent. The second chamber contains a second part of a dental sealant comprising a (meth)acrylate resin and a reducing curing agent that reacts with the oxidizing curing agent of the first chamber. The first and/or second part of the dental sealant further comprise a single component or multiple components that neutralize acid and promote remineralization. The syringe device comprises a dispensing nozzle (17) comprising a static mixer and an outlet at one end of the cartridge and a plunger (20) at the opposing end of the cartridge. Also described is a kit for storing and applying the dental sealant is described.

Abstract: An article, including a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site and a second surface opposite the first surface; wherein at least one of the interconnected polymeric stand has a plurality of features extending from the first surface of the interconnected polymeric strands; wherein at least one of the interconnected polymeric strands is non-linear; a plurality of openings between adjacent interconnected polymeric strands; an adhesive layer in contact with the second surface of the interconnected polymeric strands; and a filler in contact with the adhesive layer, the adhesive layer in between the network of interconnected polymeric strands and the filler; wherein the article is a negative pressure wound therapy article.

Abstract: A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.

Abstract: Imidazo[4,5-c]quinoline compounds of Formula (I) having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: A hardenable (e.g. dental) compositions is described comprising an encapsulated material. The encapsulated material comprises a basic core material and an inorganic shell material having certain viscosity criteria. Also described are dispensing devices and kits are described comprising a hardenable (e.g. dental) composition comprising a liquid material and an encapsulated material wherein the encapsulated material comprises a basic core material and an inorganic shell material comprising a metal oxide surrounding the core. The dispensing devices and kits can facilitate the methods of applying the hardenable composition. The hardenable or hardened (e.g. cured) composition can provide various technical effects such as a delayed release of a basic core material, a delayed increase in basicity, promoting remineralization of a tooth or bone structure, and increasing the average alkaline phosphatase (ALP) activity of pulp cells. In some embodiments, the composition is a dental (e.g.

Abstract: A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.

Abstract: An article, including a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site and a second surface opposite the first surface; wherein at least one of the interconnected polymeric stand has a plurality of features extending from the first surface of the interconnected polymeric strands; wherein at least one of the interconnected polymeric strands is non-linear; a plurality of openings between adjacent interconnected polymeric strands; an adhesive layer in contact with the second surface of the interconnected polymeric strands; and a filler in contact with the adhesive layer, the adhesive layer in between the network of interconnected polymeric strands and the filler; wherein the article is a negative pressure wound therapy article.

Abstract: An article including: a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site; wherein none of the interconnected polymeric strand has a feature extending from the first surface of the interconnected polymeric strands; wherein at least one of the interconnected polymeric strands is non-linear; and a plurality of openings between adjacent interconnected polymeric strands; wherein the article is a negative pressure wound therapy article

Abstract: A polypeptide having a sequence at least 70% identical to SEQ ID NO: 1 (YVSPGMKNVNWWSHWWHATD) is provided. The polypeptide includes no more than 100 total amino acid residues.

Abstract: An article, including a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site; wherein at least one of the interconnected polymeric strand has a plurality of features extending from the first surface of the interconnected polymeric strands; wherein only one of any two adjacent polymeric strands has a plurality of features extending from the first surface of the interconnected polymeric strands; and wherein at least one of the interconnected polymeric strands is non-linear; and a plurality of openings between adjacent interconnected polymeric strands.

Abstract: A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.

Abstract: A (e.g. hardenable dental) composition is described comprising (e.g. a first part comprising) an encapsulated material wherein the encapsulated material comprises a basic core material and an inorganic shell material comprising a metal oxide surrounding the core; and (e.g. a second part comprising) water or an acidic component. Also described is an encapsulated material (e.g. suitable for use in a biological carrier material) comprising a basic core material and an inorganic shell material comprising a metal oxide surrounding the core.

Abstract: An article, including a network of interconnected polymeric strands; wherein each of the interconnected polymeric strands has a first surface adapted to contact a tissue site; wherein at least one of the interconnected polymeric strand has a plurality of features extending from the first surface of the interconnected polymeric strands; wherein at least one of the interconnected polymeric strands is non-linear; and a plurality of openings between adjacent polymeric strands; wherein the article is a negative pressure wound therapy article.

Abstract: A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces.

Abstract: A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces.